Katharine Cuff

773 total citations
27 papers, 247 citations indexed

About

Katharine Cuff is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Katharine Cuff has authored 27 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Katharine Cuff's work include Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Advanced Breast Cancer Therapies (6 papers). Katharine Cuff is often cited by papers focused on Renal cell carcinoma treatment (7 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Advanced Breast Cancer Therapies (6 papers). Katharine Cuff collaborates with scholars based in Australia, United States and United Kingdom. Katharine Cuff's co-authors include Jeremy Lewin, Jennifer Mooi, Declan G. Murphy, Ben Tran, Shahneen Sandhu, Jeremy Goad, Sherene Loi, David Pryor, Nathan Lawrentschuk and Howard Liu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Katharine Cuff

23 papers receiving 245 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Katharine Cuff Australia	8	134	116	69	64	38	27	247
Pedro Exman United States	8	126 0.9×	255 2.2×	95 1.4×	100 1.6×	26 0.7×	21	383
Chukwuemeka Ikpeazu United States	9	144 1.1×	189 1.6×	119 1.7×	65 1.0×	42 1.1×	23	356
Giulia Grizzi Italy	12	185 1.4×	262 2.3×	82 1.2×	70 1.1×	41 1.1×	24	370
Annalisa Guida Italy	11	246 1.8×	165 1.4×	108 1.6×	72 1.1×	61 1.6×	39	323
Roby Thomas United States	7	117 0.9×	153 1.3×	56 0.8×	64 1.0×	16 0.4×	21	266
Sufia Safina Russia	9	249 1.9×	272 2.3×	85 1.2×	45 0.7×	51 1.3×	28	397
Daniela Cullurà Italy	8	205 1.5×	193 1.7×	76 1.1×	99 1.5×	62 1.6×	21	322
Matthew Labriola United States	6	159 1.2×	137 1.2×	72 1.0×	82 1.3×	28 0.7×	23	238
Leonardo Nicacio United States	10	137 1.0×	170 1.5×	40 0.6×	34 0.5×	26 0.7×	31	288
Laurence Crouzet France	7	208 1.6×	141 1.2×	155 2.2×	97 1.5×	56 1.5×	22	388

Countries citing papers authored by Katharine Cuff

Since Specialization

Citations

This map shows the geographic impact of Katharine Cuff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharine Cuff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharine Cuff more than expected).

Fields of papers citing papers by Katharine Cuff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharine Cuff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharine Cuff. The network helps show where Katharine Cuff may publish in the future.

Co-authorship network of co-authors of Katharine Cuff

This figure shows the co-authorship network connecting the top 25 collaborators of Katharine Cuff. A scholar is included among the top collaborators of Katharine Cuff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katharine Cuff. Katharine Cuff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cuff, Katharine, et al.. (2024). Medicinal Mishap: Immune checkpoint inhibitors and immune-related adverse events. Australian Prescriber. 47(5). 153–155. 1 indexed citations

Frentzas, Sophia, G. Thomas Budd, Catherine Shannon, et al.. (2024). Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients. Cancer Research. 84(9_Supplement). PO1–4. 3 indexed citations

Lok, Sheau Wen, A. Antón, Sally Baron‐Hay, et al.. (2023). Real world evidence of systemic therapy in hormone receptor positive advanced breast cancer (HR+ ABC) in Australia: ARORA Registry.. Journal of Clinical Oncology. 41(16_suppl). e13054–e13054. 1 indexed citations

Ali, Muhammad, Simon Wood, David Pryor, et al.. (2023). NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial. Contemporary Clinical Trials Communications. 33. 101145–101145. 4 indexed citations

Cuff, Katharine, et al.. (2023). Abstract OT2-10-05: HER2Pro: A Phase 1b dose de-escalation study of high dose prochlorperazine added to paclitaxel, trastuzumab and pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer. Cancer Research. 83(5_Supplement). OT2–10.

Lu, Jianqin, G. T. Budd, Sophia Frentzas, et al.. (2022). 250TiP HER2-positive and HER2-low breast cancer patients in the ACE-Pan tumor-01 study: Phase I study evaluating ARX788 as monotherapy in advanced solid tumors with HER2 expression or mutation. Annals of Oncology. 33. S223–S223. 1 indexed citations

Wong, Vanessa, Richard de Boer, Sally Baron‐Hay, et al.. (2022). Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 22(8). 792–800. 7 indexed citations

Ward, Elizabeth C., et al.. (2022). An evaluation of telephone versus videoconference consults for pre-treatment medication history taking by cancer pharmacists. Journal of Telemedicine and Telecare. 28(10). 750–756. 3 indexed citations

Pryor, David, Mathias Bressel, Nathan Lawrentschuk, et al.. (2021). A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol. Contemporary Clinical Trials Communications. 21. 100703–100703. 7 indexed citations

10.

Siva, Shankar, Mathias Bressel, Simon Wood, et al.. (2021). Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma—The RAPPORT Trial. European Urology. 81(4). 364–372. 84 indexed citations

11.

Wong, Vanessa, Richard de Boer, Sally Baron‐Hay, et al.. (2021). Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program.. Journal of Clinical Oncology. 39(15_suppl). e13018–e13018.

12.

Chan, Raymond J., Jon Emery, Katharine Cuff, et al.. (2020). Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in breast cancer post-treatment follow-up: a study protocol for a phase II randomised controlled trial (the EMINENT trial). Trials. 21(1). 855–855. 7 indexed citations

13.

Telli, Melinda L., Irene Wapnir, Bianca Devitt, et al.. (2020). Abstract P3-09-04: Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE- 890/OMS-I141). Cancer Research. 80(4_Supplement). P3–9. 11 indexed citations

14.

Siva, Shankar, Mathias Bressel, Sherene Loi, et al.. (2019). MA01.01 Safety of Pembrolizumab Combined with Stereotactic Ablative Body Radiotherapy (SABR) for Pulmonary Oligometastases. Journal of Thoracic Oncology. 14(10). S248–S248. 2 indexed citations

15.

Donskov, Frede, Robert J. Motzer, Éric Voog, et al.. (2019). Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. European Journal of Cancer. 126. 1–10. 18 indexed citations

16.

Siva, Shankar, Mathias Bressel, Shahneen Sandhu, et al.. (2019). OC-0277 Interim safety analysis of RAPPORT trial - SABR with pembrolizumab in oligometastatic RCC. Radiotherapy and Oncology. 133. S137–S137. 1 indexed citations

17.

Donskov, Frede, Robert J. Motzer, Éric Voog, et al.. (2017). Outcomes based on age in the phase 3 METEOR trial of cabozantinib (cabo) versus everolimus (eve) in patients with advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology. 35(6_suppl). 517–517. 2 indexed citations

18.

Stuart‐Harris, Robin, Arlene Chan, Dusan Kotasek, et al.. (2013). Docetaxel and cyclophosphamide as adjuvant chemotherapy for early breast cancer: primary prophylaxis with G-CSF is required. Adelaide Research & Scholarship (AR&S) (University of Adelaide). 2(5). 367–374. 7 indexed citations

19.

Cuff, Katharine, et al.. (2010). Synchronous breast cancer and lymphoma: a case series and a review of the literature. Journal of Clinical Pathology. 63(6). 555–557. 19 indexed citations

20.

Cuff, Katharine, et al.. (2010). Public and private health‐care financing with alternate public rationing rules. Health Economics. 21(2). 83–100. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact